{"nctId":"NCT03239496","briefTitle":"A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV","startDateStruct":{"date":"2017-10-23","type":"ACTUAL"},"conditions":["Poliomyelitis"],"count":773,"armGroups":[{"label":"Group A","type":"EXPERIMENTAL","interventionNames":["Biological: IPV"]},{"label":"Group B","type":"EXPERIMENTAL","interventionNames":["Biological: IPV"]},{"label":"Group C","type":"EXPERIMENTAL","interventionNames":["Biological: f-IPV"]},{"label":"Group D","type":"EXPERIMENTAL","interventionNames":["Biological: f-IPV"]}],"interventions":[{"name":"IPV","otherNames":[]},{"name":"f-IPV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Infants of 6 weeks of age (-7 to + 7 days) on date of enrollment.\n2. Healthy, as assessed from medical history and physical examination by a study physician,\n3. Written informed consent obtained from parents or legal representatives who have been properly informed about the study and are able to comply with planned study procedures.\n\nExclusion Criteria:\n\n1. Vaccinated with any poliovirus vaccine prior to inclusion,\n2. A household contact with OPV vaccination history in the past 4 weeks,\n3. HIV infection or pharmacologic immunosuppression,\n4. Known allergy to any component of the study vaccines (phenoxyethanol, formaldehyde),\n5. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular and intradermal injections,\n6. Acute severe febrile illness on day of vaccination deemed by the Investigator(s) to be a contraindication for vaccination,\n7. Not suitable for inclusion or is unlikely to comply with the protocol in the opinion of the investigator(s).","healthyVolunteers":true,"sex":"ALL","minimumAge":"5 Weeks","maximumAge":"7 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 2 Doses IPV IM","description":"To determine if the seroconversion rate of a 2-dose intradermally administered fractional-dose inactivated poliovirus vaccine (f-IPV) regimen administered at 14 and 36 weeks of age is non-inferior to that of a 2-dose intramuscularly administered inactivated poliovirus vaccine (IPV) regimen administered at 14 and 36 weeks of age for poliovirus serotypes 1 and 2.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroconversion Non-inferiority of 2 Doses IPV IM vs 3 Doses IPV IM","description":"To determine if the seroconversion rate of a 2-dose IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"98.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 3 Doses f-IPV ID","description":"To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose f-IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Superiority of 2 Doses IPV IM at Different Schedules","description":"To determine if the seroconversion rate of a 2-dose IPV regimen administered at 14 and 36 weeks of age is superior to that of a 2-dose IPV regimen administered at 10 and 14 weeks of age for poliovirus serotypes 1 and 2.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"98.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Superiority of 2 Dose f-IPV ID at Different Schedules","description":"To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is superior to that of a 2-dose f-IPV regimen administered at 10 and 14 weeks of age for poliovirus serotypes 1 and 2.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","spread":null},{"groupId":"OG001","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Non-inferiority of 2 Dose f-IPV ID vs 3 Dose IPV IM","description":"To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Non Inferiority of 3 Doses f-IPV ID vs 3 Doses IPV IM","description":"To determine if the seroconversion rate of a 3-dose f-IPV regimen administered at 10, 14, and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen also administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Non Inferiority of 3 Doses f-IPV ID vs 2 Doses IPV IM","description":"To determine if the seroconversion rate to a 3-dose regimen of f-IPV administered at 10, 14, and 36 weeks of age is non-inferior to that of a 2-dose IPV regimen administered at 14 and 36 weeks of age for poliovirus serotypes 1 and 2.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing SAEs, IMEs and/or Severe Local Reactions","description":"To assess the safety of each vaccine (IPV and f-IPV) as measured by the number of subjects experiencing serious adverse events (SAEs), important medical events (IMEs) and/or severe local reactions. This assessments is done in the Total Vaccinated Population (744 subjects).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":195},"commonTop":["Bronchiolitis","Febrile convulsion","Cow milk intolerance","Pharyngotonsillitis","Cryptorchism"]}}}